| Literature DB >> 16292511 |
Dae Y Hwang1, Jung S Cho, Chuel K Kim, Sun B Shim, Seung W Jee, Su H Lee, Su J Seo, Joon Y Cho, Seok H Lee, Yong K Kim.
Abstract
Insulin-degrading enzyme (IDE) is a 110-kDa thiol zinc-methalloendopeptidase that can cleave small Abeta peptides and the APP intracellular domain (AICD). The aim of this study was to examine aging-related correlation of IDE with gamma-secretase-generated products involving insulin and glucose levels in transgenic brains expressing neuron-specific enolase (NSE)-controlled human mutant presenilin-2 (hPS2m). Herein, we concluded that the levels of IDE expression in transgenic brains were decreased relative to those of control mice at 15 months of age. In parallel, inhibition in the IDE expression at this age underlies to the levels-up of Abeta-42, AICD, gamma-secretase, and glucose with a level-down of insulin. Thus, IDE expression is critical target for the therapeutic trials.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16292511 DOI: 10.1007/s11064-005-7952-7
Source DB: PubMed Journal: Neurochem Res ISSN: 0364-3190 Impact factor: 3.996